Most Recent
Fitness chain F45 tries to revive patents for computerised workout system
Intellectual Property 2022-03-16 5:29 pm By Sam Matthews

National fitness chain F45 has appealed a court decision revoking two of its patents for a computer-run trainer workout system, arguing its system constituted a technological innovation in the field of fitness studio franchising which rival Body Fit has profited from.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Fitness chain F45 loses patents for computer-run workout system
Intellectual Property 2022-02-15 12:56 pm By Cat Fredenburgh

A judge has revoked two patents held by national fitness chain F45 for a computer-run trainer workout system.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Pfizer wins more docs in preliminary discovery saga over Enbrel biosimilar
Intellectual Property 2021-11-18 12:46 pm By Christine Caulfield

Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Pfizer, Merck Sharpe & Dohme reach global settlement in vaccine patent battle
Intellectual Property 2021-09-24 6:25 pm By Cindy Cameronne

Pharmaceutical giants Merck Sharpe & Dohme and Pfizer have resolved a long-running intellectual property dispute over a 2015 patent owned by Pfizer for a pneumococcal vaccine.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Judge puts sandwiches back on the menu in Sizzler trade mark spat
Intellectual Property 2021-02-10 11:07 am By Miklos Bolza

A judge has ordered buffet restaurant pioneer Sizzler to amend its pleadings in a trade mark stoush with Brisbane-based restaurant Burger Urge to bring them in line with a summary judgment application that includes sandwiches among the classes of allegedly infringed goods.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Death causes six-month delay of trial in Merck, Pfizer vaccine patent dispute
Intellectual Property 2021-02-03 5:18 pm By Cat Fredenburgh

The Federal Court has delayed a 15-day hearing in a pneumococcal vaccine patent dispute between Merck Sharp & Dohme and Pfizer after the sudden death of a family member of one of Pfizer’s expert witnesses.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

The top litigation law firms of 2020
Feature 2021-01-27 11:21 pm By Cat Fredenburgh

Lawyerly’s Litigation Firms of 2020 delivered significant victories for clients last year in bet-the-company matters, thriving in a tumultuous year that saw courts and litigants adapt to virtual trials and other new norms that are sure to outlast the COVID-19 pandemic.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Merck Sharp & Dohme lodges cross appeal in Prevnar 13 vaccine patent spat
Intellectual Property 2021-01-25 4:33 pm By Christine Caulfield

Drug giant Merck Sharp & Dohme has brought a cross appeal in its long-running intellectual property dispute with Pfizer’s Wyeth over the top selling Prevnar 13 pneumococcal vaccine.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Wyeth seeks total victory in vaccine patent battle with Merck Sharp & Dohme
Intellectual Property 2021-01-15 8:53 am By Cat Fredenburgh

Pfizer unit Wyeth is seeking to overturn part of a judge’s decision in its high-stakes patent dispute with Merck Sharp & Dohme that found claims in two of its patents relating to the blockbuster Prevnar 13 pneumococcal vaccine were invalid.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Pfizer can’t get discovery in anticipation of Sandoz’ Enbrel biosimilar, judge says
Intellectual Property 2020-12-03 11:00 pm By Cat Fredenburgh

A judge hearing Pfizer’s application for preliminary discovery against Sandoz over its possible launch of an Enbrel biosimilar has found that such an application must be based on a current belief that the applicant could be entitled to relief.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?